Non Hodgkin Lymphoma Clinical Trial
Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells
Summary
RATIONALE: Analyzing genes that are present in cancer cells may be useful in developing better methods to detect, predict, and treat cutaneous T-cell lymphoma.
PURPOSE: Clinical trial to study genes that are present in cutaneous T-cell lymphoma cells.
Full Description
OBJECTIVES:
Identify gene expression patterns in malignant T cells that can be used to diagnose cutaneous T-cell lymphoma.
Determine the patterns of gene expression that distinguish normal skin-homing T cells from malignant T cells.
OUTLINE: Patients are stratified by disease (Sezary syndrome vs mycosis fungoides) and prior treatment (yes vs no).
All patients receive a physical examination, and a medical history is taken. Patients with Sezary syndrome undergo leukapheresis. Patients with plaque/tumor stage mycosis fungoides undergo skin biopsy of involved skin. Malignant T cells from blood or skin are then isolated and patterns of gene expression in the malignant T cells are compared to those in normal skin-homing T cells from healthy donors using a "gene chip" (Lymphochip).
Patients are followed annually for 5 years.
PROJECTED ACCRUAL: A total of 40 patients (20 per disease stratum) will be accrued for this study within 2 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically proven mycosis fungoides with 2 or more plaques or tumors greater than 1 cm in size OR
Immunologically proven Sezary syndrome with all of the following:
Erythroderma
Lymphadenopathy
T-cell receptor variable beta chain clonality greater than 10% of total lymphocytes by flow cytometry OR
CD4+CD7- T-cell fraction that represents greater than 10% of CD4+ T cells
PATIENT CHARACTERISTICS:
Age:
18 to 85
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
See Disease Characteristics
Hepatic:
Not specified
Renal:
Not specified
Other:
Not pregnant or nursing
HIV-1 and HTLV-1 negative
No prior intravenous drug use
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
At least 2 months since prior systemic chemotherapy
Endocrine therapy:
Not specified
Radiotherapy:
At least 2 months since prior electron beam radiotherapy
Surgery:
Not specified
Other:
At least 2 weeks since prior topical therapy
At least 2 months since prior photopheresis
At least 2 months since prior psoralen ultraviolet light (PUVA) or ultraviolet B (UVB) therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Bethesda Maryland, 20892, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.